Skip to main content
OpenTrials

Clinical trial condition

Malignant Ovarian Mixed Epithelial Tumor

Explore clinical trials studying Malignant Ovarian Mixed Epithelial Tumor. Study availability and eligibility vary by location and protocol.

5 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

Malignant Ovarian Mixed Epithelial Tumor trial results

Completed

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

NCT00262847

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +48 more
Locations
  • Northeast Alabama Regional Medical Center Anniston, Alabama, United States
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Clearview Cancer Institute Huntsville, Alabama, United States
  • Mobile Infirmary Medical Center Mobile, Alabama, United States
View all 632 locations
View Trial Details
Completed

A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00939809

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +31 more
Locations
  • Georgia Regents University Medical Center Augusta, Georgia, United States
  • University of Iowa Hospitals and Clinics Iowa City, Iowa, United States
  • Nebraska Methodist Hospital Omaha, Nebraska, United States
  • Stony Brook University Medical Center Stony Brook, New York, United States
View all 16 locations
View Trial Details
Completed

Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

NCT00814086

Conditions
Adnexal Diseases, Brenner Tumor, Chemically-Induced Disorders, +40 more
Locations
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • University of Iowa Hospitals and Clinics Iowa City, Iowa, United States
  • Cooper Hospital University Medical Center Camden, New Jersey, United States
  • Riverside Methodist Hospital Columbus, Ohio, United States
View Trial Details
Completed

TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

NCT01294293

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +31 more
Locations
  • Gynecologic Oncology Group of Arizona Phoenix, Arizona, United States
  • Saint Joseph's Hospital and Medical Center Phoenix, Arizona, United States
  • University of Colorado Cancer Center - Anschutz Cancer Pavilion Aurora, Colorado, United States
  • University of Iowa Hospitals and Clinics Iowa City, Iowa, United States
View Trial Details

Related conditions